AC 607

Drug Profile

AC 607

Alternative Names: AC607; Allogeneic multipotent stromal cell treatment - AlloCure; Allogeneic stem cell therapy - AlloCure

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator AlloCure
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute kidney injury
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute kidney injury

Most Recent Events

  • 28 Jul 2015 Discontinued - Phase-II for Acute kidney injury in Canada (Parenteral)
  • 28 Jul 2015 Discontinued - Phase-II for Acute kidney injury in USA (Parenteral)
  • 01 Aug 2014 Allocure completes a phase II trial in Acute kidney injury in USA and Canada (NCT01602328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top